N/A N=15 Acupressure in Pruritus for Atopic Dermatitis
Atopic Dermatitis
Primary: Change in Itch Intensity as Measured by a Change in Visual Analog Scale (VAS) Score — 0.8; -5.0 centimeters
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=41 Secukinumab for Treatment of Atopic Dermatitis
Atopic Dermatitis
Primary: Fold-Change in Epidermal Thickness of Lesional Skin — 1.15; 1.5; 1.18; -1 fold-change
Phase 4 N=54 Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis
Dermatitis Atopic
Primary: Change From Baseline in Intraepidermal Nerve Fiber Density on Lesional Skin at Week 17 — 8.4567; 4.2618 F/mm^2
N/A N=9 Reversal of Epidermal Phenotype in Severe Atopic Dermatitis With Cyclosporine Therapy
Atopic Dermatitis · Eczema
Primary: SCORAD Change Score — 33.34 Change Score
Phase 2 N=35 Double-Blind Lamictal (Lamotrigine) in Neurotic Excoriation
Neurotic Excoriation · Pathologic Skin Picking · Psychogenic Excoriation
Primary: The Yale-Brown Obsessive Compulsive Scale Modified for Neurotic Excoriation (NE-YBOCS) Will be the Primary Outcome Measure — 15.25; 16.13 units on a scale
N/A N=1,260 A Community-based Assessment of Skin Care, Allergies, and Eczema
Atopic Dermatitis · Atopic Disorders · Eczema
Primary: Provider-diagnosed Atopic Dermatitis — 217.7; 268.5 Participants with imputed values — p=0.019
Phase 2 N=226 Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Atopic Dermatitis
Primary: Percent Change From Baseline in Eczema Area and Severity Index (EASI) at Week 24 — -58.4; -72.2; -73.4; -69.2 percentage change — p=0.051
Phase 2 N=60 Randomized Placebo Controlled Study to Determine Safety, Pharmacodynamics and Efficacy of ILV-094 in Atopic Dermatitis
Atopic Dermatitis
Primary: Percentage Change in SCORAD — -18.8; -11.7 percentage change
Phase 3 N=941 Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
Moderate-to-Severe Atopic Dermatitis
Primary: Percentage of Participants With an Investigator's Global Assessment (IGA) Success (IGA of 0 or 1 and a More Than Equal to [>=] 2-point Reduction): Intent-To-Treat (ITT)…
Phase 3 N=787 Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
Moderate-to-Severe Atopic Dermatitis
Primary: Percentage of Participants With Investigator's Global Assessment (IGA) Success at Week 16: Intent-To-Treat (ITT) Population — 37.7; 26.0 percentage of participants…
N/A N=148,166 Trends in the Epidemiology and Treatment of Atopic Dermatitis in the United Kingdom (UK)
Atopic Dermatitis Eczema · Atopic Dermatitis · Eczema
Primary: Prescription Rates for Atopic Dermatitis Related Treatments: Emollients and Soap Substitutes — 76095 Participants
Phase 2 N=32 Pilot Study of Ustekinumab for Subjects With Chronic Atopic Dermatitis
Atopic Dermatitis
Primary: Proportion of SCORAD-50 Response at Week 16. — 5; 3 Participants
Phase 2 N=484 Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis
Pruritus · Atopic Dermatitis
Primary: Change in WI-NRS From Baseline to Week 6 — -2.25; -2.32; -2.01 score on a scale
Phase 2 N=20 Effect of Benralizumab in Atopic Dermatitis
Dermatitis, Atopic · Dermatitis · Eczema
Primary: Number of Allergen-induced Eosinophils in the Skin — 11.95; 71.15 cells/mm2
Phase 2 N=3 Safety Study of Elidel (Pimecrolimus) 1% Cream to Treat Netherton Syndrome
Netherton Syndrome
Primary: Blood Pimecrolimus Levels — 0; 0; 0.312; 1.260 ng/mL
Phase 2 N=20 Topical Aprepitant in Prurigo Patients
Pruritus
Primary: Pruritus by VAS (Visual Analogue Scale) — 19.7; 21.2 mm — p=0.58
Phase 3 N=65 8-Week Atopic Dermatitis (AD) Treatment Study
Atopic Dermatitis Eczema
Primary: Severity Scoring of Atopic Dermatitis (SCORAD) Amongst Subjects With Moderate Atopic Dermatitis — -12.2; 9.3; -17.5 units on a scale — p=<0.05
Phase 2 N=40 Topical Roflumilast in Adults With Atopic Dermatitis
Atopic Dermatitis
Primary: Change From Baseline to Day 15 in Modified Local SCORing Atopic Dermatitis (SCORAD) — -2.30; -1.75 Scores on a scale — p=0.276
Phase 2 N=200 A NOVel Moisturiser for Atopic Dermatitis: Effect on the Skin Barrier
Dermatitis, Atopic
Primary: Skin Barrier Strengthening Effect by Measurement of Trans Epidermal Water Loss (TEWL) Before and After Induction of Skin Irritation — 19.790; 24.680; 29.648; 28.646 TEWL…
Phase 2 N=61 Urticaria Facticia Treatment With Omalizumab (UFO)
Symptomatic Dermographism
Primary: Change in Provocation Thresholds From Baseline to Day 70 in Urticaria Factitia Patients After Treatment With Omalizumab Compared to Placebo — -1.8; -2.0; -0.6 wheal…
Phase 2 N=12 Study of Apremilast in Atopic or Contact Dermatitis
Atopic Dermatitis · Allergic Contact Dermatitis
Primary: Number of Patients Achieving an Improvement (Decrease) in IGA (Investigator Global Assessment) by Two or More Points — 2 participants
Phase 3 N=326 Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects
Atopic Dermatitis
Primary: Percentage of Participants Who Had at Least a 2-grade Reduction From Baseline at Week 6 in the Investigator Global Assessment (IGA) Scale and Had an IGA at Week 6 That…
Phase 4 N=40 Management of Pruritus With Xyzal in Atopic Dermatitis
Atopic Dermatitis · Pruritus
Primary: Pruritus VAS Scores at Baseline, Week 2 and Week 4 — 7.8; 7.5; 6.10; 5.9 units on a scale
Phase 4 N=90 Combination Therapy for Atopic Dermatitis
Atopic Dermatitis
Primary: Change From Baseline in the m-EASI (Eczema Area Severity Index) Score. — 5.04; 4.77 units of a 0-12 scale — p=<0.05
Phase 2 N=168 Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis
Atopic Dermatitis
Primary: Mean Change From Baseline in Pruritus Symptoms, as Measured by the 24-hour Average Pruritus Visual Analogue Scale (VAS) Score — -41.5; -35.8 score on a scale
Phase 4 N=25 Adherence to Topical Hydrocortisone 17-butyrate 0.1% (Locoid®) Using Different Vehicles in Adults With Atopic Dermatitis
Atopic Dermatitis
Primary: Adherence to Locoid — .55; .60; .50 percentage of days
Phase 2 N=15 Topical NanoDox® for Atopic Dermatitis
Dermatitis, Atopic
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 0 Participants
N/A N=108 Pruritus in Patients With Chronic Kidney Disease
Kidney Failure, Chronic · Pruritus
Primary: Visual Analog Scale (VAS) — 3.35 units on a scale
Phase 4 N=24 Evaluating Treatment Resistant Dermatitis TaroIIR
Atopic Dermatitis · Psoriasis
Primary: Investigator Global Assessment- Atopic Dermatitis — 1.7; 1.5 units on a scale
Phase 3 N=353 PRISM Study-Pruritus Relief Through Itch Scratch Modulation
Prurigo Nodularis
Primary: Percentage of Participants With ≥ 4- Point Decrease in 7-day Average Worst Itch - Numerical Rating Scale (WI-NRS) up to Week 14 — 24.24; 14.50 percentage of participants…